TECHNOLOGY DESCRIPTION
Our innovation:
Innovative in vitro method for diagnosis, prognosis and monitoring of Alzheimer's disease (AD) using the metabolic profile in serum of an individual.
The new method includes a sample preparation and NMR acquisition protocol, a mathematical algorithm and a suitable software for data processing.
The mathematical model applies not only the biomarkers identified as relevant, but the complete metabolomic profile of the sample.
The method has both high sensitivity and specificity which are suitable for clinical use.
Reproducible data acquisition within the same patient as well as with different individuals.
The method allows the early diagnosis of the disease and monitoring the evolution of patients with suspected AD.
Potentially this invention might be useful for differential diagnosis between AD and other dementias.
BENEFITS
Competitive advantages: Non-invasive and economic in vitro analysis. High sensitivity (94%) and specificity (88%). Suitable for clinical use. Reliable method based on plurality of metabolites. Individualized quantification of metabolites is not necessary.
LIMITATIONS
To be determined during further development.
APPLICATIONS
Patient need addressed: Alzheimer’s disease.
Readiness Level (TRL)
 Patent Grading Report |
Patent Grading ReportThe Grading Patents Report evaluates and grades US patents Sample Buy from Wisdomain |
STATUS
Current status
Spanish patent application (Priority date: March 23, 2020). Suitable for International extension (PCT application)
AVAILABILITY
Available for
Licensing or Assignment
INVENTOR / TEAM
M. Carmen Martinez, Ramon Martinez, Miguel Calero, Miguel Medina, Ana Belen Pastor
